Poster Highlighting Qualigen Therapeutics’ Pan-RAS Inhibitor Platform Presented at American Society of Clinical Oncology (ASCO) 2023 Annual Meeting
June 05 2023 - 7:15AM
Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a diversified life
sciences company focused on developing treatments for adult and
pediatric cancers with potential for Orphan Drug Designation, while
also commercializing diagnostics, announces today that a poster
featuring the Company’s pan-RAS inhibitor program in pancreatic
cancer will be presented as part of the Scientific Program at the
American Society of Clinical Oncology’s (ASCO) 2023 Annual Meeting
held June 2-6, 2023 in Chicago.
Michael Poirier, Qualigen's Chairman and CEO,
commented, “Our scientific programs continue to focus on orphan
indications, including pancreatic cancer, and we are gratified that
data regarding our novel pan-RAS inhibitor platform were accepted
as a poster. The data continue to be encouraging, even at this
early stage, and we continue to collaborate with the University of
Louisville (UofL) Research Foundation in the development of this
entire program. As we remain on track toward identifying a lead
candidate later this year, we appreciate the opportunity to share
these findings at the ASCO meeting.”
Abstract #4155 “Impact of novel pan-RAS
inhibitors on efficacy and resistance to AMG-510 and MRTX-1133 in
pancreatic cancer cell lines.” Howard Donninger, Rachel Ferrill,
Becca Von Baby, Joe Burlison, John O. Trent, Michael Sabo, Tariq
Arshad, Geoffrey J. Clark
Poster Board #476
The poster outlines results of concurrent
administration of the Company’s pan-RAS inhibitor molecules with
commonly used therapeutics against pancreatic cancer. In vivo
activity was confirmed in xenograft experiments with cell lines and
PDX models, and the molecules were shown to co-operate with AMG-510
(sotorasib) (G12C specific inhibitor) and MRTX1133 (G12D specific
inhibitor) against pancreatic cancer cell lines. The agents were
also shown to suppress resistance to MRTX1133 in vitro, which led
authors to believe these pan-RAS compounds may overcome resistance
to AMG-510 and MRTX1133 in vivo.
The Company had two abstracts accepted to the
meeting, the other of which is “A novel pan-RAS inhibitor for
luminal B breast cancer.” Tariq Arshad, Howard Donninger, Mike
Sabo, John Trent, Geoffrey J. Clark, Joe Burlison. This abstract
can be found in the ASCO 2023 Annual Meeting Abstract Book.
Qualigen’s pan-RAS inhibitor platform is a
family of small molecules designed to prevent mutated RAS gene
proteins from binding to their effector proteins. Exclusively
in-licensed from UofL, compounds from this discovery engine have
been shown to impact tumor growth in multiple in vivo models.
Qualigen is evaluating promising compounds generated from this
partnership in various RAS-driven advanced solid tumors such as
pancreatic, breast, colorectal, and lung cancers.
About Qualigen
Therapeutics, Inc.
Qualigen Therapeutics, Inc. is a diversified
life sciences company focused on developing treatments for adult
and pediatric cancer, while also commercializing diagnostics. Our
investigational QN-302 compound is a small molecule selective
transcription inhibitor with strong binding affinity to G4s
prevalent in cancer cells; such binding could, by stabilizing the
G4s against “unwinding,” help inhibit cancer cell proliferation.
The investigational compounds within Qualigen’s family of RAS
oncogene protein-protein interaction inhibitor small molecules are
believed to inhibit or block the binding of mutated RAS genes’
proteins to their effector proteins, thereby leaving the proteins
from the mutated RAS unable to cause further harm. In theory, such
mechanism of action may be effective in the treatment of about one
quarter of all cancers, including certain forms of pancreatic,
colorectal, and lung cancers. Our investigational QN-247 compound
inhibits nucleolin, a key multi-functional regulatory protein that
is overexpressed in cancer cells; QN-247 may thereby be able to
inhibit the cells’ proliferation. QN-247 has shown promise in
preclinical studies for the treatment of acute myeloid leukemia
(AML). In addition to its oncology drug pipeline, Qualigen has an
established diagnostics business which manufactures and distributes
proprietary and highly accurate rapid blood testing systems to
physician offices and small hospitals for the management of
prostate cancer and other diseases and health conditions.
For more information about Qualigen
Therapeutics, Inc., please visit www.qualigeninc.com.
Contact:
Jules AbrahamJQA Partners,
Inc.917-885-7378jabraham@jqapartners.com
- Qualigen Therapeutics, Inc.
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From Apr 2024 to May 2024
Qualigen Therapeutics (NASDAQ:QLGN)
Historical Stock Chart
From May 2023 to May 2024